How Analysts Feel About Cambrex Corporation (NYSE:CBM)?

April 15, 2018 - By Nellie Frank

Investors sentiment decreased to 1.15 in Q4 2017. Its down 0.43, from 1.58 in 2017Q3. It dived, as 33 investors sold Cambrex Corporation shares while 71 reduced holdings. 38 funds opened positions while 82 raised stakes. 32.02 million shares or 1.25% more from 31.63 million shares in 2017Q3 were reported.
The New York-based Pinebridge Invests L P has invested 0.04% in Cambrex Corporation (NYSE:CBM). Keybank Natl Association Oh invested in 0% or 5,215 shares. Arizona State Retirement has 0.03% invested in Cambrex Corporation (NYSE:CBM) for 55,091 shares. Penn Cap Mngmt Co invested in 263,227 shares or 0.89% of the stock. Portolan Cap Mngmt Lc stated it has 144,881 shares or 0.76% of all its holdings. Bnp Paribas Arbitrage invested 0% of its portfolio in Cambrex Corporation (NYSE:CBM). Dupont Capital Mgmt Corp reported 9,163 shares. Polaris Cap Mngmt Lc owns 0.09% invested in Cambrex Corporation (NYSE:CBM) for 24,482 shares. 973,805 are owned by Clearbridge Investments Limited Liability Corp. Piedmont Advsrs Lc holds 0.01% or 6,737 shares. Dubuque Natl Bank &, a Iowa-based fund reported 3,539 shares. Bankshares Of America Corp De holds 0% or 233,782 shares. Credit Suisse Ag has invested 0% in Cambrex Corporation (NYSE:CBM). Two Sigma Lc reported 4,309 shares. 400 were reported by Pacad Inv.

Cambrex Corporation (NYSE:CBM) Ratings Coverage

Among 3 analysts covering Cambrex Corp (NYSE:CBM), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Cambrex Corp had 3 analyst reports since October 31, 2017 according to SRatingsIntel. William Blair maintained Cambrex Corporation (NYSE:CBM) on Tuesday, January 16 with “Buy” rating. As per Wednesday, February 14, the company rating was downgraded by Longbow. The stock has “Buy” rating by Craig Hallum on Tuesday, October 31. Below is a list of Cambrex Corporation (NYSE:CBM) latest ratings and price target changes.

14/02/2018 Broker: Longbow Old Rating: Buy New Rating: Neutral Downgrade
16/01/2018 Broker: William Blair Rating: Buy Maintain
31/10/2017 Broker: Craig Hallum Rating: Buy New Target: $60.0 Maintain

It closed at $54.4 lastly. It is down 2.87% since April 15, 2017 and is uptrending. It has underperformed by 8.68% the S&P500.

Cambrex Corporation, a life sciences company, provides various services and products for the development and commercialization of new and generic therapeutics worldwide. The company has market cap of $1.79 billion. The companyÂ’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. It has a 17.77 P/E ratio. It serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics.

Cambrex Corporation (NYSE:CBM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.